Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

NCT03904719
unknownphase_2

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

NCT03848611
unknownphase_2

Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

NCT03602547

Clinical Trials (3)

Showing 3 of 3 trials
NCT03904719Phase 2

CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)

Unknown
NCT03848611Phase 2

CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Unknown
NCT03602547Phase 2

Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3